AU2021269176A1 - Single domain antibodies binding to SARS-CoV-2 spike protein - Google Patents

Single domain antibodies binding to SARS-CoV-2 spike protein Download PDF

Info

Publication number
AU2021269176A1
AU2021269176A1 AU2021269176A AU2021269176A AU2021269176A1 AU 2021269176 A1 AU2021269176 A1 AU 2021269176A1 AU 2021269176 A AU2021269176 A AU 2021269176A AU 2021269176 A AU2021269176 A AU 2021269176A AU 2021269176 A1 AU2021269176 A1 AU 2021269176A1
Authority
AU
Australia
Prior art keywords
seq
cdr3
cdr2
cdr1
single domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021269176A
Other languages
English (en)
Other versions
AU2021269176A8 (en
Inventor
Jiandong HUO
James Naismith
Raymond Owens
David Stuart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosalind Franklin Institute
Original Assignee
DIAMOND LIGHT SOURCE Ltd
Oxford University Innovation Ltd
Rosalind Franklin Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006589.2A external-priority patent/GB202006589D0/en
Priority claimed from GBGB2010861.9A external-priority patent/GB202010861D0/en
Application filed by DIAMOND LIGHT SOURCE Ltd, Oxford University Innovation Ltd, Rosalind Franklin Institute filed Critical DIAMOND LIGHT SOURCE Ltd
Publication of AU2021269176A1 publication Critical patent/AU2021269176A1/en
Publication of AU2021269176A8 publication Critical patent/AU2021269176A8/en
Assigned to THE ROSALIND FRANKLIN INSTITUTE reassignment THE ROSALIND FRANKLIN INSTITUTE Request for Assignment Assignors: DIAMOND LIGHT SOURCE LIMITED, OXFORD UNIVERSITY INNOVATION LIMITED, THE ROSALIND FRANKLIN INSTITUTE
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2021269176A 2020-05-04 2021-05-04 Single domain antibodies binding to SARS-CoV-2 spike protein Abandoned AU2021269176A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2006589.2A GB202006589D0 (en) 2020-05-04 2020-05-04 Single domain antibodies
GB2006589.2 2020-05-04
GBGB2010861.9A GB202010861D0 (en) 2020-07-14 2020-07-14 Single domain antibodies
GB2010861.9 2020-07-14
PCT/GB2021/051069 WO2021224606A1 (en) 2020-05-04 2021-05-04 Single domain antibodies binding to sars-cov-2 spike protein

Publications (2)

Publication Number Publication Date
AU2021269176A1 true AU2021269176A1 (en) 2022-11-24
AU2021269176A8 AU2021269176A8 (en) 2022-12-08

Family

ID=75977769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021269176A Abandoned AU2021269176A1 (en) 2020-05-04 2021-05-04 Single domain antibodies binding to SARS-CoV-2 spike protein

Country Status (7)

Country Link
US (1) US20230348572A1 (https=)
EP (1) EP4146689A1 (https=)
JP (1) JP2023524573A (https=)
KR (1) KR20230150184A (https=)
AU (1) AU2021269176A1 (https=)
CA (1) CA3177766A1 (https=)
WO (1) WO2021224606A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104933A1 (en) * 2021-12-07 2023-06-15 new/era/mabs GmbH Camelid antibodies for use in therapy and diagnosis
EP4194054A1 (en) * 2021-12-07 2023-06-14 new/era/mabs GmbH Camelid antibodies for use in therapy and diagnosis
CN114478757B (zh) * 2022-03-31 2022-07-05 深圳市人民医院 靶向新冠病毒的纳米抗体及其制备方法和应用
CN114736293B (zh) * 2022-06-14 2022-09-02 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用
WO2025147701A1 (en) * 2024-01-07 2025-07-10 Abalone Bio, Inc. Cannabinoid receptor type 2 antibodies and uses thereof
WO2026006639A1 (en) * 2024-06-26 2026-01-02 Rutgers, The State University Of New Jersey Antigen binding molecules targeting transferrin receptor 1
GB202413879D0 (en) 2024-09-20 2024-11-06 Rosalind Franklin Inst Single domain antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333722A (zh) 2020-03-03 2020-06-26 江苏省疾病预防控制中心(江苏省公共卫生研究院) SARS-CoV-2抑制剂及其应用
CN114163523B (zh) 2020-03-17 2023-07-18 北京凯因科技股份有限公司 一种针对新型冠状病毒的单域抗体及其应用
CN111647076B (zh) 2020-04-27 2021-02-26 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用

Also Published As

Publication number Publication date
AU2021269176A8 (en) 2022-12-08
KR20230150184A (ko) 2023-10-30
US20230348572A1 (en) 2023-11-02
CA3177766A1 (en) 2021-11-11
JP2023524573A (ja) 2023-06-12
WO2021224606A1 (en) 2021-11-11
EP4146689A1 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
Huo et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Dejnirattisai et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dang et al. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
Nutalai et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
US20230348572A1 (en) Single domain antibodies binding to sars-cov-2 spike protein
Li et al. High potency of a bivalent human VH domain in SARS-CoV-2 animal models
Muecksch et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Huo et al. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
Zhang et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
Wang et al. Structural definition of a neutralization-sensitive epitope on the MERS-CoV S1-NTD
Zhou et al. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein
Bianchini et al. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Dang et al. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
Rossey et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
US20240043507A1 (en) Antibodies
Wen et al. Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode
CN121127489A (zh) 靶向sars-cov-2的抗原结合分子
Errico et al. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
Chen et al. Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains
EP4230650B1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
US20250154231A1 (en) Antibodies capable of binding to the spike protein of cononavirus sars-cov-2
Liu et al. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge
Cornish et al. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2
Huo et al. Structural characterisation of a nanobody derived from a naïve library that neutralises SARS-CoV-2

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF A CO-INVENTOR TO READ HUO, JIANDONG

TH Corrigenda

Free format text: IN VOL 36 , NO 47 , PAGE(S) 6453 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES ROSALIND FRANKLIN INSTITUTE; VDIAMOND LIGHT SOURCE LIMITED; OXFORD UNIVERSITY INNOVATION LIMITED, APPLICATION NO. 2021269176, UNDER INID (71) CORRECT THE APPLICANT NAMES TO THE ROSALIND FRANKLIN INSTITUTE; DIAMOND LIGHT SOURCE LIMITED

PC1 Assignment before grant (sect. 113)

Owner name: THE ROSALIND FRANKLIN INSTITUTE

Free format text: FORMER APPLICANT(S): DIAMOND LIGHT SOURCE LIMITED; THE ROSALIND FRANKLIN INSTITUTE; OXFORD UNIVERSITY INNOVATION LIMITED

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period